Identification of Common CD8+ T cell Epitopes from Lassa Fever Survivors in Nigeria and Sierra Leone

Saori Sakabe\textsuperscript{a}, Jessica N. Hartnett\textsuperscript{b}, Nhi Ngo\textsuperscript{a}, Augustine Goba\textsuperscript{c,d}, Mambu Momoh\textsuperscript{c,d,e}, John Demby Sandi\textsuperscript{c,d,f}, Lansana Kanneh\textsuperscript{c,d}, Beatrice Cubitt\textsuperscript{a}, Selma D. Garcia\textsuperscript{a}, Brian C. Ware\textsuperscript{a}, Dylan Kotliar\textsuperscript{g}, Refugio Robles-Sikisaka\textsuperscript{a,h}, Karthik Gangavarapu\textsuperscript{i}, Luis M. Branco\textsuperscript{j}, Philomena Eromon\textsuperscript{k}, Ikponmwosa Odia\textsuperscript{l}, Ephraim Ogbaini-Emovon\textsuperscript{l}, Onikepe Folarin\textsuperscript{k,m}, Sylvanus Okogbenin\textsuperscript{l}, Peter O. Okokhere\textsuperscript{j,n,o}, Christian Happi\textsuperscript{k,l,m}, Pardis C. Sabeti\textsuperscript{g,p,q}, John S. Schieffelin\textsuperscript{s}, Michael B.A. Oldstone\textsuperscript{a}, and Brian M. Sullivan\textsuperscript{a,*}

\textsuperscript{a} Viral-Immunobiology Laboratory, Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA
\textsuperscript{b} Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA
\textsuperscript{c} Viral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone
\textsuperscript{d} Ministry of Health and Sanitation, Freetown, Sierra Leone
\textsuperscript{e} Eastern Polytechnic Institute, Kenema, Sierra Leone
\textsuperscript{f} Njala University, Moyamba, Sierra Leone
\textsuperscript{g} FAS Center for Systems Biology, Harvard University, The Broad Institute of MIT and Harvard, Cambridge, MA
\textsuperscript{h} Scripps Translational Research Institute, The Scripps Research Institute, La Jolla, CA
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA

Zalgen Labs, Germantown, MD

African Center of Excellence for Genomics of Infectious Disease (ACEGID), Redeemers University, Ede, Nigeria

Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria

Department of Biological Sciences, Redeemers University, Ede, Nigeria

Department of Medicine, Irrua Specialist Teaching Hospital, Irrua, Nigeria

Department of Medicine, Faculty of Clinical Sciences, Ambrose Alli University, Ekpoma, Nigeria.

SHERLOCK Biosciences, Cambridge, MA

Danaher Corporation, Washington, DC

College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone

Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA

Running Head: Common T Cell Epitopes of Lassa Virus

Address correspondence to Brian M. Sullivan, bsully@scripps.edu
This is manuscript #29936 from The Scripps Research Institute.

Word Count

Abstract: 145

Text: 3,631
Abstract

Early and robust T cell responses have been associated with survival from Lassa fever (LF), but the Lassa virus-specific memory responses have not been well-characterized. Regions within the virus surface glycoprotein (GPC) and nucleoprotein (NP) are the main targets of the Lassa virus-specific T cell responses, but to date only a few T cell epitopes within these proteins have been identified. We identified GPC and NP regions containing T cell epitopes and HLA haplotypes from LF survivors and used predictive HLA binding algorithms to identify putative epitopes which were then experimentally tested using autologous survivor samples. We identified 12 CD8+ T cell epitopes, including epitopes common to both Nigerian and Sierra Leonean survivors. These data should be useful for identification of dominant Lassa virus-specific T cell responses in Lassa fever survivors and vaccinated individuals as well as for designing vaccines that elicit cell mediated immunity.

Importance

The high morbidity and mortality of associated with clinical cases of Lassa fever together with the lack of licensed vaccines and limited and partially effective interventions make Lassa virus (LASV) an important health concern in its endemic regions in West Africa. Previous infection with LASV protects from disease after subsequent exposure, providing a framework for designing vaccines to elicit similar protective immunity. Multiple major lineages of LASV circulate in West Africa and...
therefore ideal vaccine candidates should elicit immunity to all lineages. We, therefore, sought to identify common T cell epitopes between Lassa fever survivors from Sierra Leone and Nigeria, where distinct lineages circulate. We identified three such epitopes that derived from highly conserved regions within LASV proteins. In this process, we also identified nine other T cell epitopes. These data should help in the design of an effective pan-LASV vaccine.

Introduction

Lassa fever (LF), a hemorrhagic illness caused by infection with the Old World mammarenavirus, Lassa virus (LASV) is an important health concern in its endemic regions of West Africa due to high morbidity and mortality among hospitalized patients. Limited health care infrastructure in rural West Africa impedes the study of LF in humans difficult. This difficulty is compounded by the classification of LASV as a biosafety level 4 pathogen.

Despite the challenges in assessing immune responses during LF, evidence indicates that T cell responses are critical for control and clearance of acute LASV infection,(1) with robust T cell responses observed in human and non-human primate LF survivors(2, 3). In contrast, antibody responses are slow to develop, with neutralizing antibodies detected only months after viremia has cleared(2, 4, 5). Despite their importance during acute infection, T cell responses to LASV infection in humans have been poorly
characterized. A case study of an infected healthcare worker described robust CD4+ and CD8+ T cell responses, a prolonged CD8+ T cell response, and a delayed LASV-specific IgG response (2). A separate study of eight LF survivors from the Republic of Guinea showed proliferative CD4+ T cell responses in response to NP antigen. Six CD4+ T cell epitopes with variable cross-reactivity to Lassa lineage-specific sequences were described for one of these patients (6).

Previous infection with LASV appears to protect against LF after re-exposure to LASV, but the contribution of cell mediated and humoral immunity to protection from subsequent exposure remains to be determined. A recent LASV-challenge study in non-human primates found that NHPs vaccinated with a measles virus vector encoding both the GPC and NP induced nearly sterilizing immunity after a single dose while control of viremia was not as effective when NP was excluded (7). This finding is consistent with our observations that the majority of LASV survivors harbor T cells that respond to both NP and GPC (8).

Ideally, a LASV vaccine should protect against strains of all major lineages of LASV found in geographically distinct areas of West Africa. These lineages coincide with regional populations of *Mastomys natalensis*, the major natural reservoir of LASV (9-15). Previously, we documented that LF survivors with LASV-specific CD8+ T cell responses to antigens from one lineage respond to antigens from a different LASV lineage (8). We also found that specific regions of the LASV glycoprotein complex (GPC) and nucleoprotein (NP) harbor the majority of T cell epitopes against LASV (8). Here, we
identify peptide epitopes present within these regions and identify common T cell epitopes between Nigerian and Sierra Leonean LF survivors.

Results

To identify LASV-specific CD8 T cells, we created a library of recombinant single cycle vesicular stomatitis virus (rscVSV) encoding LASV antigens (NP, GP1, GP2) and 60 amino acid (aa) polypeptides (herein: fragments) derived from these antigens (Table 1) from the lineage IV Josiah strain. We detected mRNA and protein expression in rscVSV infected BHK-21 cells for NP and GP1, but only mRNA expression for GP2 and each of the ~60 aa polypeptides. Importantly, we observed robust CD8+ T cell responses following infection of human peripheral blood mononuclear cells (PBMCs) with rscVSV expressing antigens for which only mRNA was readily detected.

Using these reagents, we sought to identify LASV specific CD8+ T cell responses to NP and GPC as well as responses to regions within these viral proteins to identify sequences that harbor T cell epitopes. We use antigens from lineage IV viruses which circulate in Sierra Leone to stimulate T cell responses from Sierra Leonean and Nigerian survivors, despite latter likely infected with lineage II and III LASV. We previously described results indicating comparable CD8+ T cell responses between Nigerian and Sierra Leonean LF survivors to lineage IV antigens.
PBMCs from Sierra Leonean and Nigerian LF survivors were incubated overnight with rscVSVs encoding for GP1, GP2 (Figure 1A), NP (Figure 1B), and overlapping fragments from each antigen (Figure 1) and assessed for intracellular expression of interferon (IFN)-γ and tumor necrosis factor (TNF)-α. We observed no responses in two donors from the United States with no previous travel to Africa and in three Sierra Leonean individuals with no history of LF and who were seronegative at the time of blood collection (Figure 2). We observed CD8+ T cell responses to rscVSVs encoding LASV GPC and the NP in four LF survivors (N-13, 2889600, 2848950, and 8397490) while we observed CD8+ T cell responses to rscVSVs encoding LASV GPC but not those encoding NP in LF survivors N-07 and 3568610 (Figure 1). As there was no response to the NP, stimulations with rscVSVs encoding overlapping fragments derived from NP sequences were not performed.

We used information from T cell responses to overlapping fragments to deduce epitope containing regions as described (8, 16). If we observed IFN-γ and TNF-α expressing CD8+ T cells in response to rscVSVs encoding two adjacent overlapping sequences, we deduced that the epitope containing region (or deduced epitope) occurs in the overlapping sequence. If we observed IFN-γ and TNF-α expressing CD8+ T cells in response to one rscVSV and no response to rscVSVs encoding adjacent sequences, we deduced that the epitope-containing region occurs in the non-overlapping region plus an additional seven amino acids in the overlapping regions on either side. These additional amino acids account for most epitopes that would have been only partially encoded by rscVSVs encoding adjacent sequences. Most deduced epitopes were
different between Nigerian and Sierra Leonean survivors (8), but we identified individuals from both survivor groups that had T cell responses to common regions within the NP and GPC (Table 2).

To further examine the presence of shared peptide epitopes between Sierra Leonean and Nigerian survivors and to identify smaller epitopes within these regions, we utilized MHC class I-binding prediction algorithms hosted by the Immune Epitope Database (www.iedb.org) to identify putative epitopes for further testing. To reduce the number of peptide candidates and to limit potential false positive epitopes that might be generated if we were to use entire LASV NP or GPC sequences, we restricted this analysis to the deduced epitopes identified earlier that were specific for HLA expression of each individual. We tested peptides with <2.0% percentile rank based on predicted affinity unless there were less than three candidates under 2.0%. In such cases, we tested at least the top three candidates regardless of percentile rank (Table 2). We stimulated autologous PBMCs from the survivors with 10-aa peptide epitope candidates for five hours, followed by staining and flow cytometry analysis of IFN-γ and TNF-α expression by CD8+ T cells.

Nigerian LF survivor N-13 and Sierra Leonean LF survivor 2848950 both responded to NP fragment 13 (f13: NP<sub>508-569</sub>) while no response was observed to rscVSVs encoding the adjacent fragment 12 (f12: NP<sub>457-527</sub>; Figures 3A & 3B) implicating the region encompassed by NP<sub>521-569</sub> as containing a minimal epitope. The HLAs expressed by N-13 and 2848950 were predicted to bind five and eight peptides, respectively, within
NP\textsubscript{521-569}. We incubated these peptides with PBMCs from each survivor and found that CD8\(^+\) T cells responded to epitope NP\textsubscript{552-561} in both survivors (Figure 3C & 3D). In silico MHC class I-binding prediction ranked HLA-A*74:01 binding to NP\textsubscript{552-561} highest (netmhcpan; percentile rank 0.09\%) among HLA alleles expressed by these two individuals. HLA-A*74:01 is the only allele shared by these two LF survivors and is the most likely restriction for NP\textsubscript{552-561}.

Survivor 2848950 also responded to NP\textsubscript{557-566} and NP\textsubscript{558-567}. CD8\(^+\) T cell responses to NP\textsubscript{557-566} and NP\textsubscript{558-567} were similar (Figure 3D, 0.039\% and 0.042\% of CD8\(^+\) T cells, respectively). This result strongly suggests that these T cells may respond to a smaller 9aa epitope, NP\textsubscript{558-556}, though this peptide was not tested due to lack of additional PBMC sample.

We also interrogated the carboxy terminus of GP1 based on the conservation of deduced epitope regions between Nigerian and Sierra Leonean survivors. CD8\(^+\) T cells from Nigerian survivor N-07 and Sierra Leonean survivor 3568610 co-expressed IFN-\(\gamma\) and TNF-\(\alpha\) in response to rscVSVs encoding GPC f6 (GPC\textsubscript{194-256}) but not to surrounding fragments f5 (GPC\textsubscript{153-212}) or f7 (GPC\textsubscript{240-299}), suggesting the existence of epitope within GPC\textsubscript{206-246} (Figure 4A & 4B). We tested the top seven putative peptide epitopes using cells from N-07 and top five putative peptide epitopes using cells from 3568610 and found strong responses to GPC\textsubscript{235-244} in both individuals (Figure 4C & 4D) with a weaker response to GPC\textsubscript{233-242} only in 3568610 (Figure 4D). Though both individuals have CD8\(^+\) T cell responses to GPC\textsubscript{235-244}, they do not share a common class I allele. HLA-
B*81:01 (expressed by N-07) and HLA-B*07:06 (expressed by 3568610) were predicted having the highest affinity for GPC_{235-244} (netmhcpan; percentile ranking 0.03 for both alleles).

CD8+ T cells from Nigerian survivor N-13 and Sierra Leonean survivors 2889600 and 2848950 responded to rscVSVs encoding GPC f6 (GPC_{194-256}) and f7 (GPC_{240-299}) (Figure 5A, 5B, & 5C). Responses to GPC f6 and f7 were comparable in CD8+ T cells from N-13 and 2889600 (Figure 5A & 5B) while 2848950 responded robustly only to GPC f6 (Figure 5C). A weak CD8+ T cell response f7 from survivor 2848950 (Figure 5C) led us to test nine peptides derived from a larger region (GPC_{206-259}), whereas the pool of peptide epitope candidates tested in PBMCs from N-13 (three peptides) and 2889600 (four peptides) were limited to sequences within the deduced epitope (GPC_{240-259}). All three LF survivors responded to GPC_{248-257} while 2889600 and 2848950 also responded to GPC_{247-256} (Figure 5D, 5E, & 5F). Similar T cell responses to GPC_{248-257} and GPC_{247-256} (Figure 5E & 5F) suggested these responses were to the single epitope GPC_{248-256} but we did not test directly this peptide epitope candidate due to lack of PBMC sample. No common HLAs were shared among all three individuals. However, N-13 and 2848950 both express HLA-A*74:01:01 while 2889600 and 2848950 share HLA-A*34:02:01. HLA-A*74:01:01 and HLA-A*34:02:01 are the top ranked alleles predicted to bind GPC_{248-257} (netmhcpan; percentile rank 0.09 and 0.55, respectively).

To assess if epitopes common between Nigerian survivors, NP_{552-561}, GPC_{235-244}, and GPC_{248-257}, were more conserved than areas outside these regions, we analyzed the
extent of amino acid conservation using 600 LASV NP and GPC sequences (Lineage II: 420; lineage III: 49; lineage IV: 131). We found a high degree of amino acid conservation within epitopes shared by Nigerian and Sierra Leonean survivors (NP552-561, GPC235-244, and GPC248-257) compared to non-epitope protein regions (99.30% vs 94.66%, p=0.0193, two-tailed Mann-Whitney test). Individually, amino acid conservation for NP552-561 is 99.5%, for GPC235-244 is 99.4%, and GPC248-257 is 99.0%.

In addition to epitopes shared between Nigerian and Sierra Leonean LF survivors, we found an additional five 10-aa peptide epitopes (Figure 6) using the methodology described above. We observed robust CD8+ T cell responses to T cell epitopes derived from NP and GPC sequences with the greatest responses to NP155-164, NP453-462, and GPC235-244 (Figure 6A, 6B, 6C). We also found CD8+ T cell responses from two LF survivors to a previously described HLA-A2-restricted epitope, GPC60-68 (Figure 6A, 6B, 6C) (17). Both patients (3568610 and 8397490) with CD8+ T cell responses to this epitope express the HLA-A*02:01 allele. The same report (17) identified GPC441-449 as an HLA-A2-restricted epitope. While CD8+ T cells from 5513520 responded to a similar epitope, GPC440-449, this LF survivor does not harbor the HLA-A*02:01 allele suggesting this epitope has multiple restrictions.

Discussion

We identified 11 peptide epitopes that produced CD8+ T cell responses from six LF survivors in both Nigeria and Sierra Leone. To our knowledge, only two of these
epitopes have been previously described (2, 17) and this is the first study to identify CD8+ T cell epitopes from human LF survivors. Because we measured responses to whole LASV antigens, the epitopes can be placed in context of both other peptide epitopes in the same individual as well as in context of responses to the major antigenic proteins, NP and GPC, thereby revealing the comparative dominance of responses in each individual. We have also used this approach to identify T-cell epitopes from Ebola survivors in Sierra Leone (16).

By delivering antigen through viral infection, the important biological mechanisms of antigen processing and presentation are maintained. Retaining these processes helps reduce the potential for cross-reactive T cells that were not generated or expanded during LASV infection. We were especially concerned about this possibility as T cell responses are shaped early against a variety of pathogens in the antigen rich environments of developing countries (18, 19). To reduce potential false positive responses, we delivered LASV antigens through infection with rscVSVs to limit the number of peptides from a particular antigen that would naturally be presented by an antigen presenting cell (20-22) thereby limiting potential false positive responses. Other approaches, including the use of overlapping peptide pools, have been successfully used to identify T cell epitopes from a number of different infections (17, 23-26).

However, this approach typically necessitates large numbers of PBMCs and subsequent rigorous validation. We were able to identify peptides epitopes from individuals with only 30 mL of blood, a limit imposed by our human subjects approved protocol.
Due to these sample restrictions, we were unable to perform biological replicates in our experiments and relied on a consistency of CD8+ T cell responses to rscVSVs encoding whole antigens and ~60aa fragments and to peptide epitopes. To reduce the possibility of identifying false epitopes, we instituted a robust criterion for positive epitopes, namely 1.2 logs increase in both IFN-γ and TNF-α expression instead of using increases in single cytokine expression. Weaker LASV-specific T cell responses or responses that resulted in the expression of a single cytokine may have been missed.

We had identified regions within GPC and NP that were more likely to harbor CD8+ T cell epitopes from Nigerian and Sierra Leonean LF survivors. We expected to find many common epitopes between these two groups of LF survivors. Instead we found only a few smaller epitope regions in common. We were also surprised to find a lack of common HLA alleles among individuals with responses to the T-cell epitopes reported in the present study. No common alleles were found between individuals whose CD8+ T cells responded to GPC_{235-244}. Similarly, no single HLA allele was found in common between all three survivors whose T cells responded to GPC_{248-256}, though two alleles predicted to bind the epitope were found in two of the three responders. We also observed a diverse set of individual-specific epitopes.

The LASV genome only encodes for four proteins, two of which typically harbor the majority of dominant T cell epitopes. Consequently, we, and others, have suggested that common epitopes could be encoded sequentially like "beads on a string"
to maximize T cell reactivity while minimizing coding length (17, 33, 34). Because of our
observations of highly immunogenic regions within the GPC and NP and the diversity of
epitopes in these areas, it may be more prudent to design an immunogen that
incorporates these highly immunogenic regions and not simply the smaller epitopes
themselves. Importantly, we found these regions to be high conserved between
lineages. This approach may lead to a greater protection across populations with a
diverse set of HLAs.

LASV epitope identification efforts have been focused on epitopes that may be
presented by common HLAs (17, 35). Three LASV epitopes restricted to HLA-A*02,
GPC42-50, GPC60-68, and GPC441-449, were identified through HLA binding and murine
studies and shown to be protective in mice challenged with recombinant vaccinia virus
encoding LASV GPC (17). Two LF survivors in our study express HLA-A*02:01 and we
found that GPC60-68 peptide elicited responses in these individuals. Sierra Leonean LF
survivor 8397490 responded to GPC f2 (GPC40-98), f11 (GPC404-463), and weakly to f1
(GPC1-58), which contain the previously identified GPC60-68, GPC441-449, and GPC42-50,
respectively, epitopes (REF). Sierra Leonean LF survivor 3568610, who also responded
to GPC60-68, did not respond to GPC f2 or f11, and only very weakly to f1. This result
could indicate a lack of sensitivity of our assay, a subdominant response from these
previously identified epitopes, a cross-reactive response of using the peptide alone, or a
combination thereof.
Multiple factors are responsible for the selection and dominance of epitope specific T cells and associated responses during an acute viral infection, including: 1) precursor frequency,(36) 2) strength and stability of peptide-MHC binding to its cognate TCR,(37) 3) expression of the antigen,(38, 39) 4) the extent and manner in which these antigens are processed and presented,(40) and 5) the contribution of amino acids flanking the anchoring residues.(41) We identified twelve 10-aa peptide epitopes based on responses to whole LASV antigens and ~60 aa polypeptides delivered by rscVSVs. Several epitopes were common among LF survivors, but HLAs were not universally conserved among LF survivors with common epitopes. Our data indicate that even for viruses with low proteomic complexity, there may be substantial variability in epitope specific responses among individuals. Therefore, to elicit broad CD8+ T cell responses in diverse populations across West Africa, vaccines should deliver either whole antigens or encode those regions within the NP and GPC that we have identified as regions that elicit LASV specific responses in the majority of survivors studied.

Materials and Methods

Subjects. This study was approved by the following institutions: Human Subjects Committees of the Broad Institute, The Scripps Research Institute, Tulane University’s Human Research Protection Program, the Sierra Leone Ethics and Scientific Review Committee, ISTH Research and Ethics Committee, and the Oyo State Research Ethical Review Committee. All subjects have a documented history of Lassa fever. Because of
the manner in which samples were coded at the time of collection, no demographic, disease, or virus sequence information is available for the Nigerian participants. Demographic information and time from disease onset to analysis of memory responses for Sierra Leonean patients are listed in Table 3.

Sample collection and PBMC isolation. Blood was collected in EDTA vacutainers at the Kenema Government Hospital (Kenema, Sierra Leone) or at the Irrua Specialist Teaching Hospital (Irrua, Nigeria). PBMC isolation was performed according to standard protocols. Briefly, blood was diluted three times with PBS and layered onto Lymphoprep (StemCell Technologies) or lymphocyte separation medium (MP Biochemicals) and centrifuged at 1450rpm without break. Buffy coat layer was isolated and washed twice with PBS before resuspended in CryoStor CS10 (StemCell Technologies), slow frozen at -80°C for 3 hours and stored in a liquid nitrogen dry shipper for shipment to the United States for analysis.

rscVSV preparation and usage. Plasmids used to rescue rscVSVs expressing LASV antigens have been described (8, 42, 43). LASV sequences were based on Josiah strain from lineage IV. rscVSVs were rescued and characterized as described(8). PBMCs from LF survivors were incubated with rscVSVs at a multiplicity of infection (MOI) of 15 in a U-bottom 96 well plate. After 4 hours, brefelding A (4 μg/ml) was added and cells were incubated overnight (~16 hours) at 37 °C in 5% CO₂ before staining with the following antibodies: anti-human brilliant violet 421 CD4 (RPA-T4) (BioLegend), FITC CD8a (HIT8a) (Biolegend), anti-human PE TNF-α (BD Biosciences), PE/Cy7 IFN-
γ (4S.B3) (BD Biosciences), and APC IL-2 (MQ1-17H12) (BD Biosciences). BD Fixation/Permeabilization kit was used for intracellular stains. Positive controls were treated similarly except for incubation with unlabeled anti-human CD3 (clone: OKT-3; BioXCell; 60 μg/ml) and CD28 (clone: 9.3; BioXCell; 20 μg/ml) instead of rscVSVs.

Peptide stimulations. Peptide stimulations were performed at a concentration of 10 μg/ml (unpurified, Anaspec). After 1 hour stimulation, brefeldin A (4 μg/ml) was added and cultures were incubated for an additional 4 hours at 37°C in 5% CO2.

Peptide-MHC class I binding prediction. Deduced epitope sequences and HLA profiles (Table 2) were entered into the MHC-I Binding Prediction tool ((v2013-02-22) at the IEDB website (www.iedb.org) to generate a list of putative epitopes. We used the recommended settings (Consensus and NetMHCpan) and selected all 10aa peptides below the 2% prediction ranking for testing.

HLA typing. As previously described(16), genomic DNA was extracted from 1 x 10^6 PBMCs using the Quick DNA Miniprep Plus Kit (Zymo Research) and quality assessed by electrophoretic separation on an 0/8% agarose gel. For long-range amplification and library preparation, we used the TruSight HLA v2 Sequencing Panel (CareDx) followed by sequencing of barcoded libraries on the Illumina MiSeq platform. Lastly, TruSight HLA Assign software (v2.1 RUO) was used to analyze results and compared with sequences stored in the International ImMunoGeneTics Information System/HLA.
A reference DNA sample, IHW09263, was used for each sequencing experiment.

Data availability. All epitopes, including longer deduced epitopes and 10-aa peptide epitopes along with associated HLA alleles, have been submitted to the Immune Epitope Database (www.iedb.org; submission IDs: 1000831, 1000832, and 1000836).

In addition, more information on our subjects, including HLAs, is stored online by the Center for Viral Systems Biology (www.cvisb.org).

Acknowledgments

BMS, CH, JCT, KGA, RG, DSG, JSS, and MBAO designed the studies. BMS, SS, NN, BC, SG, BCW, DK, RRS, LMB, and KG conducted the experiments. BMS, SS, JCT, and MBAO analyzed the data and wrote the manuscript. JNH, AG, MM, JDS, LK, PE, IO, EOE, OF, SO, PO, DG, and JSS enrolled participants, collected samples, and maintained biorepository databases, including clinical information and outcomes. BMS, RG, DSG, KGA, CH, and MBAO provided project administration and oversight.

We would like to thank the clinical staff at Kenema Government Hospital and the Lassa Ward, especially Francis Baimba for his expertise in phlebotomy as well as Simbirie Jalloh for managing the Lassa fever program at the KGH.
We report the following potential conflicts of interest: RFG and LMB are co-founders of Zalgen Labs, LLC. The Viral Hemorrhagic Fever Consortium (vhfc.org) is a partnership of academic and industry scientists who are developing diagnostics, therapeutics and vaccines for LF and other severe diseases. Tulane University and various industry partners have filed United States and foreign patent applications on behalf of the consortium for several of these technologies. If commercial products are developed, consortium members may receive royalties or profits.

This is manuscript #29936 from The Scripps Research Institute.

This work was funded by NIAID contract grant HHSN272201400048C under BAA-NIAID-DAIT-NIHAI2013167 and NIH grant 1R01AI123535.
References

1. Flatz L, Rieger T, Merkler D, Bergthaler A, Regen T, Schedensack M, Bestmann L, Verschoor A, Kreutzfeldt M, Bruck W, Hanisch UK, Gunther S, Pinschewer DD. 2010. T cell-dependence of Lassa fever pathogenesis. PLoS Pathog 6:e1000836.

2. McElroy AK, Akondy RS, Harmon JR, Ellebedy AH, Cannon D, Klena JD, Sidney J, Sette A, Mehta AK, Kraft CS, Lyon MG, Varkey JB, Ribner BS, Nichol ST, Spiropoulou CF. 2017. A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses. J Infect Dis 215:1862-1872.

3. Buize S, Marianneau P, Loth P, Reynard S, Journeaux A, Chevallier M, Tordo N, Deubel V, Contamin H. 2009. Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J Virol 83:5890-903.

4. Johnson KM, McCormick JB, Webb PA, Smith ES, Elliott LH, King IJ. 1987. Clinical virology of Lassa fever in hospitalized patients. J Infect Dis 155:456-64.

5. Fisher-Hoch SP, McCormick JB, Auperin D, Brown BG, Castor M, Perez G, Ruo S, Conaty A, Brammer L, Bauer S. 1989. Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proc Natl Acad Sci U S A 86:317-21.

6. ter Meulen J, Badusche M, Kuhnt K, Doetze A, Satoguina J, Marti T, Loeliger C, Koulemou K, Koivogui L, Fleischer B, Hoerauf A. 2000. Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein. J Virol 74:2186-92.

7. Mateo M, Reynard S, Carnec X, Journeaux A, Baillet N, Schaeffer J, Picard C, Legras-Lachuer C, Allan R, Perthame E, Hillion KH, Pietrosemoli N, Dillies MA, Barrot L, Vallve B, Barron S, Fellmann L, Gaillard JC, Armengaud J, Carbonnelle C, Raoul H, Tangy F, Baize S. 2019. Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot. Sci Transl Med 11.

8. Sullivan BM, Sakabe S, Hartnett JN, Ngo N, Goba A, Momoh M, Sandi JD, Kanneh L, Cubitt B, Garcia SD, Ware BC, Kotliar D, Robles-Sikisaka R, Gire SK, Branco LM, Eronmon P, Iponmowa O, Ogbaini-Emovon E, Folarin OA, Okogbenin S, Okohere PO, Happi C, de la Torre JC, Garry RF, Grant DS, Schieffelin JS, Oldstone MBA. in press. High Crossreactivity of Human T Cell Responses Between Lassa Virus Lineages. PLoS Pathog.

9. Andersen KG, Shapiro BJ, Matranga CB, Sealfon R, Lin AE, Moses LM, Folarin OA, Goba A, Odia I, Ehiane PE, Momoh M, England EM, Winnicki S, Branco LM, Jeremiah, Phelan E, Tariyal R, Tewhey R, Omoniwa O, Pullah M, Fonnie R, Fonnie M, Kanneh L, Jalloh S, Gbakie M, Saffa S, Karbo K, Gladden AD, Qu J, Stremlau M, Nekoui M, Finucane HK, Tabrizi S, Vitti J, Birren B, Fitzgerald M, McCowan C, Ireland A, Berlin AM, Bochicchio J, Tazon-Vega B,ennon NJ, Ryan EM, Bjornson Z, Milner DA, Jr., Lukens AK, Broodie N, Rowland M, Heinrich M, Akdag M, et al. 2015. Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus. Cell 162:738-50.

10. Fichet-Calvet E, Rogers DJ. 2009. Risk maps of Lassa fever in West Africa. PLoS Negl Trop Dis 3:e388.

11. Lecompte E, Fichet-Calvet E, Daffis S, Koulemou K, Sylla O, Kourouma F, Dore A, Soropoguie B, Aniskin V, Allali B, Kouassi Kan S, Lalas A, Koivogui L, Gunther S,
Denys C, ter Meulen J. 2006. Mastomys natalensis and Lassa fever, West Africa. Emerg Infect Dis 12:1971-4.

Whitmer SLM, Strecker T, Cadar D, Dienes HP, Faber K, Patel K, Brown SM, Davis WG, Klena JD, Rollin PE, Schmidt-Chanasit J, Fichet-Calvet E, Noack B, Emmerich P, Riegert W, Wolff S, Fehling SK, Eickmann M, Mengel JP, Schultze T, Hain T, Ampofo G, De Leuw P, Schuettfort G, Stephan C, Wieland U, Fries JWU, Kochanek M, Kraft CS, Wolf T, Nichol ST, Becker S, Stroher U, Gunther S. 2018. New Lineage of Lassa Virus, Togo, 2016. Emerg Infect Dis 24:599-602.

13. Ehichioya DU, Dellicour S, Pahlmann M, Rieger T, Oestereich L, Becker-Ziaja B, Cadar D, Ighodalo Y, Olokor T, Omomoh E, Oyakhilome J, Omiunu R, Agbukor J, Ebo B, Aiyepada J, Ebhodaghe P, Omiunu R, Airende M, Enigbe R, Yerumoh EO, Bockholt S, Kaftanzopoulou LE, Duraffour S, Okohkere PO, Akpede GO, Okogbenin E, Giwa R, Ekanem A, Odigie G, Okonofua G, Esumeh R, Muoebonam E, Igenegbale G, Odia I, Aire C, Akpede N, Tobin E, Ogbaini-Emovon E, Lehey P, Adomeh DI, Asogun DA, Gunther S. 2019. Phylogeography of Lassa virus in Nigeria. J Virol doi:10.1128/JVI.00929-19.

14. Manning JT, Forrester N, Paessler S. 2015. Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage. Front Microbiol 6:1037.

15. Bowen MD, Rollin PE, Ksiazek TG, Hustad HL, Bausch DG, Demby AH, Bajani MD, Peters CJ, Nichol ST. 2000. Genetic diversity among Lassa virus strains. J Virol 74:6992-7004.

16. Sakabe S, Sullivan BM, Hartnett JN, Robles-Sikisaka R, Gangavarapu K, Cubitt B, Ware BC, Kotliar D, Branco LM, Goba A, Momoh M, Sandi JD, Kanneh L, Grant DS, Garry RF, Andersen KG, de la Torre JC, Sabeti PC, Oldstone MBA. 2018. Analysis of CD8(+) T cell response during the 2013-2016 Ebola epidemic in West Africa. Proc Natl Acad Sci U S A 115:E7578-E7586.

17. Botten J, Alexander J, Pasquotto V, Sidney J, Barrowman P, Ting J, Peters B, Southwood S, Stewart B, Rodriguez-Carreno MP, Mothe B, Whitton JL, Sette A, Buchmeier MJ. 2006. Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J Virol 80:8351-61.

18. Wagar LE, Bolen CR, Sigal N, Lopez Angel CJ, Guan L, Kirkpatrick BD, Haque R, Tibshirani RJ, Parsonnet J, Petri WA, Jr., Davis MM. 2019. Increased T Cell Differentiation and Cytolytic Function in Bangladeshi Compared to American Children. Front Immunol 10:2239.

19. Worku S, Christensson B, Bjorkman A, Islam D. 1997. Higher proportion of CD8+ T cells in the blood in healthy adults from Ethiopia and Bangladesh compared with Sweden. Trans R Soc Trop Med Hyg 91:618-22.

20. Brett SJ, Cease KB, Berzofsky JA. 1988. Influences of antigen processing on the expression of the T cell repertoire. Evidence for MHC-specific hindering structures on the products of processing. J Exp Med 168:357-73.

21. Schellens IM, Hoof I, Meirin HD, Spijkers SN, Poel MC, van Gaans-van den Brink JA, van der Poel K, Costa AI, van Els CA, van Baarle D, Kesmir C. 2015. Comprehensive Analysis of the Naturally Processed Peptide Repertoire: Differences between HLA-A and B in the Immunopeptidome. PLoS One 10:e0136417.
22. Freudenmann LK, Marcu A, Stevanovic S. 2018. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry. Immunology 154:331-345.

23. Dhanda SK, Mahajan S, Paul S, Yan Z, Kim H, Jespersen MC, Jurtz V, Andreatt M, Greenbaum JA, Marcatili P, Sette A, Nielsen M, Peters B. 2019. IEDB-AR: immune epitope database-analysis resource in 2019. Nucleic Acids Res 47:W502-W506.

24. Fiore-Gartland A, Manso BA, Friedrich DP, Gabriel EE, Finak G, Moodie Z, Hertz T, De Rosa SC, Frahm N, Gilbert PB, McElrath MJ. 2016. Pooled Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials. PLoS One 11:e0147812.

25. Tian Y, da Silva Antunes R, Sidney J, Lindestam Arlehamn CS, Grifoni A, Dhanda SK, Paul S, Peters B, Weiskopf D, Sette A, Weiskopf D, Sette A, Nielsen M, Peters B, Weiskopf D, Sette A. 2019. IEDB-AR: immune epitope database-analysis resource in 2019. Nucleic Acids Res 47:W502-W506.

26. Fiore-Gartland A, Manso BA, Friedrich DP, Gabriel EE, Finak G, Moodie Z, Hertz T, De Rosa SC, Frahm N, Gilbert PB, McElrath MJ. 2016. Pooled Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials. PLoS One 11:e0147812.
37. Harndahl M, Rasmussen M, Roder G, Dalgaard Pedersen I, Sorensen M, Nielsen M, Buus S. 2012. Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. Eur J Immunol 42:1405-16.

38. Apcher S, Daskalogianni C, Lejeune F, Manoury B, Imhoos G, Heslop L, Fahraeus R. 2011. Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation. Proc Natl Acad Sci U S A 108:11572-7.

39. Golovina TN, Morrison SE, Eisenlohr LC. 2005. The impact of misfolding versus targeted degradation on the efficiency of the MHC class I-restricted antigen processing. J Immunol 174:2763-9.

40. Assarsson E, Sidney J, Oseroff C, Pasquetto V, Bui HH, Frahm N, Brander C, Peters B, Grey H, Sette A. 2007. A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J Immunol 178:7890-901.

41. Hudrisier D, Mazarguil H, Laval F, Oldstone MB, Gairin JE. 1996. Binding of viral antigens to major histocompatibility complex class I H-2Db molecules is controlled by dominant negative elements at peptide non-anchor residues. Implications for peptide selection and presentation. J Biol Chem 271:17829-36.

42. Moseley NB, Laur O, Ibegbu CC, Loria GD, Ikwuenzunma G, Jayakar HR, Whitt MA, Altman JD. 2012. Use of replication restricted recombinant vesicular stomatitis virus vectors for detection of antigen-specific T cells. J Immunol Methods 375:118-28.

43. Whitt MA. 2010. Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J Virol Methods 169:365-74.
Figure 1: CD8+ T cell responses from LF survivors from Nigeria (N) and Sierra Leone (SL). (A) PBMCs were incubated with rscVSVs encoding EGFP (negative control), GP1, GP2, or ~60 amino acid polypeptides derived from GPC sequences overnight in the presence of brefelin A. Cells were surface stained for CD3e and CD8 before fixation, permeabilization, and staining with antibodies against TNF-α and IFN-γ. Graphs indicate the percentage of CD3+CD8+ cells positive for both TNF-α and IFN-γ by flow cytometry. Positive gates were set at a mean fluorescence intensity of >1.2log_{10} over the median negative control and dotted horizontal lines indicate levels of highest negative control sample (no stim or EGFP). (B) Same as (A) except PBMCs were incubated with rscVSVs encoding for NP and associated polypeptides. CD8+ T cell responses to NP using PBMCs from N-07 and 3568610 were considered negative and responses to NP fragments were not assessed.

Figure 2: CD8+ T cell responses to rscVSV encoding EGFP and LASV antigens GP1, GP2, and NP as well as unstimulated controls were assessed in two US donors with no history of travel to West Africa and three Sierra Leoneans seronegative for LASV.

Figure 3: CD8+ T cell responses to NP antigens from a Nigerian (N-13) and Sierra Leonean (2848950) LF survivor. PBMCs from N-13 (A) and 2848950 (B) were incubated with rscVSVs encoding LASV NP and NP fragments (designated by a “f”) and evaluated by intracellular staining of IFN-γ and TNF-α flow cytometry. The ability of T cells to produce IFN-γ and TNF-α after engagement of the TCR was evaluated by
incubation with antibodies against CD3 and CD28. Candidate peptide epitopes were identified by in silico MHC class I prediction algorithms using reactivity to NP fragments and HLAs expressed by each LF survivor. The top predicted peptide epitopes were incubated with PBMCs from N-13 (C) and 2848950 (D) for five hours in the presence of brefeldin A and CD3+CD8+ cells were evaluated by intracellular staining of IFN-γ and TNF-α flow cytometry.

Figure 4: CD8+ T cell responses to GPC antigens from a Nigerian (N-07) and Sierra Leonean (3568610) LF survivor. PBMCs from N-07 (A) and 3568610 (B) were incubated with rscVSVs encoding LASV GPC and GPC fragments (designated by an “f”) and evaluated by intracellular staining of IFN-γ and TNF-α flow cytometry. Candidate peptide epitopes were identified as explained in Figure 2. The top predicted peptide epitopes were incubated with PBMCs from N-07 (C) and 3568610 (D) for five hours in the presence of brefeldin A and CD3+CD8+ cells were evaluated by intracellular staining of IFN-γ and TNF-α flow cytometry.

Figure 5: CD8+ T cell responses to GPC antigens from a Nigerian (N-13) and two Sierra Leonean (2889600, 2848950) LF survivors. PBMCs from N-13 (A), 2889600 (B), and 2848950 (C) were incubated with rscVSVs encoding LASV GPC and GPC fragments (designated by an “f”) and evaluated by intracellular staining of IFN-γ and TNF-α flow cytometry. Candidate peptide epitopes were identified as explained in Figure 2. The top predicted peptide epitopes were incubated with PBMCs from N-13 (D), 2889600 (E), and 2848950 (F) for five hours in the presence of brefeldin A and
CD3+CD8+ cells were evaluated by intracellular staining of IFN-γ and TNF-α flow cytometry.

Figure 6: Additional seven 10aa peptide epitopes discovered from LF survivors. (A) Candidate peptide epitopes were identified through in silico prediction of MHC class I binding using reactivity to NP or GPC fragments and HLAs expressed be each LF survivor. Unstimulated and positive epitopes are shown. Epitopes were considered positive if we observed ≥3 events double positive for IFN-γ and TNF-α over the unstimulated controls. (B) Graph depicting percentages of CD3+CD8+ cells double positive for IFN-γ and TNF-α in response to all candidate epitopes tested for each individual. Red empty circles indicate negative epitopes. Data from each patient is from a single experiment. GPC epitopes are denoted by circle with a black outline while NP epitopes are not outlined. Common epitopes are denoted by common colors while epitopes only found in a single individual are grey. C) CD8+ T cell responses to epitopes GPC\textsubscript{233-242}, GPC\textsubscript{235-244} and GPC\textsubscript{60-68} from independent experiments. D) CD8+ T cell responses in duplicate from LF survivor 2889600 to a positive epitope, NP\textsubscript{554-563}, and a negative epitope, GPC\textsubscript{442-451}.

Table 1: Amino acid positions encoded by rscVSVs expressing LASV antigens.

| Antigen | AA Position |
|---------|-------------|
| GP1     | 1-279       |
| GP2     | 214-491     |
| GPC-f1  | 1-58        |
| GPC-f2  | 34-93       |
| GPC-f3  | 75-134      |
| GPC-f4  | 115-174     |
Table 2. HLA (Class I) profiles, deduced epitopes, and peptide sequences with top predicted restriction and percentile rank for each. Peptides in blue indicate positive epitopes.

| Subject & HLAs | Deduced Epitope | Peptide Sequence | Peptide Position | Predicted Restriction | Percent Rank |
|---------------|-----------------|------------------|------------------|-----------------------|--------------|
| N-07          | GPC 206-245     | GNWDCIMTSY       | GPC 208-217      | A*2902                | 1.14         |
| A*290201      |                 | WDCIMTSYQY       | GPC 210-219      | A*2902                | 0.94         |
| A*660101      |                 | CIMTSYQYLI       | GPC 212-221      | B*5301                | 1.02         |
| B*530101      |                 | TWEDHCQFSR       | GPC 226-235      | C*0401                | 9.4          |
| B*8101       |                 | HCFQSRPSPPI      | GPC 230-239      | A*6601                | 8.2          |
| C*040101      |                 | FSRPSPIGYL       | GPC 233-242      | C*1801                | 0.9          |
| C*1801        |                 | RPSPIGYLGL       | GPC 235-244      | B*8101                | 0.03         |
| N-13          | GPC 240-259     | YLGLLSQQRTR      | GPC 241-250      | A*7401                | 1.6          |
| A*330301      |                 | LSQRTRDIYI       | GPC 245-254      | B*5301                | 7.25         |
| A*740101      |                 | RTRDIYSRR        | GPC 248-257      | A*7401                | 0.09         |
| A*740101      |                 | MSASKEIKSF       | NP 1-10          | C*0302                | 2.0          |
| B*530101      |                 | ASKEIKSFLW       | NP 3-12          | B*5801                | 0.48         |
| B*580101      |                 | IKSFLWTQSL       | NP 7-16          | C*0302                | 4.0          |
| B*580101      |                 | SFLWTQSLRR       | NP 9-18          | A*3303                | 0.32         |
| HLA          | Peptide                  | Start | End    | B*5801 | B*5301 | A*0201 | A*020101 | A*070101 | A*2301 | A*3402 | A*340201 | A*7401 | B*0702 | B*450101 | B*070201 | B*350101 | B*490101 |
|--------------|--------------------------|-------|--------|--------|--------|--------|----------|----------|--------|--------|----------|--------|--------|----------|----------|----------|----------|
| C*030202     | KDAQALLHGL               | 33    | 42     | 2.85   | 1.45   | 2.65   | 0.94     | 0.08     | 3.1    | 0.55   | 2.3      |        |        |          |          |          |          |
| C*030202     | TPHCALMDCI               | 521   | 569    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
|              | NP 526-535               |       |        | B*5301 |        |        |          |          |        |        |          |        |        |          |          |          |          |
|              | NP 528-537               |       |        | B*5301 |        |        |          |          |        |        |          |        |        |          |          |          |          |
|              | NP 547-556               |       |        | A*3303 |        |        |          |          |        |        |          |        |        |          |          |          |          |
|              | NP 552-561               |       |        | A*7401 |        |        |          |          |        |        |          |        |        |          |          |          |          |
|              | NP 554-563               |       |        | B*5301 |        |        |          |          |        |        |          |        |        |          |          |          |          |
|              | NP 557-566               |       |        | A*3303 |        |        |          |          |        |        |          |        |        |          |          |          |          |
|              | NP 560-569               |       |        | C*0302 |        |        |          |          |        |        |          |        |        |          |          |          |          |
| 3568610      | GPC 206-246              | 206   | 246    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| A*020101     | CIMSUSYQYLI              | 206   | 212    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| A*230101     | SYQYLIQNT                | 212   | 221    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| B*070601     | QYLIIQNTTW               | 221   | 225    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| B*450101     | FSRPSPIGYL               | 225   | 233    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| C*070201     | RPSPIGYLGL               | 233   | 242    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| C*1601@8     |                            |       |        |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| 2889600      | GPC 240-259              | 240   | 259    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| A*340201     | LSQRTRDIYI               | 240   | 254    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| B*070201     | QRTRDIYISR               | 254   | 257    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| B*420101     | RTRDIYISRR               | 257   | 259    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| C*070201     | RDIYISRLLL               | 259   | 262    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| C*170101     |                            |       |        |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| A*300101     | ATQPGLTSAV               | 424   | 449    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| A*340201     | LPNRMVITCQ               | 449   | 453    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| B*070201     | KDIKLIIDIAL              | 453   | 462    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| B*420101     | IKLIDIALSK               | 462   | 477    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| C*070201     | KYENAVWDQY               | 477   | 488    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| C*170101     | TPHCALMDCI               | 488   | 502    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| A*340201     | NP 518-535               | 502   | 507    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| B*070201     | RAVLPRDMVF               | 507   | 521    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| B*420101     | AVLPRDMVFR               | 521   | 526    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| C*070201     | TPRDMVFRTS               | 526   | 535    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| C*170101     | NP 551-560               | 535   | 551    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| A*740101     | NP 552-561               | 551   | 557    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| B*070201     | NP 557-566               | 557   | 566    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| B*490101     | MVFRSTPRV                | 566   | 577    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| B*070201     | NP 560-569               | 577   | 587    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| B*490101     | MVFRSTPRV                | 587   | 598    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| 2848950      | GPC 206-290              | 206   | 240    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| A*340201     | HCQFSRPSPI               | 240   | 259    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| A*740101     | QFQFSRPSPI               | 259   | 270    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| B*350101     | FSRPSPIGYL               | 270   | 283    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| B*490101     | SRPSPIGYLG               | 283   | 292    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| B*350101     | YISRRLLGTF               | 292   | 301    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| B*490101     | GPC 240-259              | 301   | 323    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| B*740101     | YLGLLSQRTR               | 323   | 341    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
| B*490101     | QTRTRDIYISR              | 341   | 350    |        |        |        |          |          |        |        |          |        |        |          |          |          |          |
Table 3. Demographic information for LF survivors.

| N  | Age at infection | Sex    | Years from infection to convalescent blood draw |
|----|------------------|--------|-----------------------------------------------|
| 07*| Unknown          | Unknown| Unknown                                      |
| 13*| Unknown          | Unknown| Unknown                                      |
| ID     | Year | Gender | Age | Abdominal Blood Pressure |
|--------|------|--------|-----|--------------------------|
| 3568610| 2013 | F      | 5.9 | 2889600                  |
| 2848950| 2013 | M      | 7.8 | 28397490                 |
| 8397490| 2013 | F      | 0.1 | 662                      |

* Convalescent blood collected in 2013.
